Pancreatic cancer genomics: where can the science take us?

@article{Graham2015PancreaticCG,
  title={Pancreatic cancer genomics: where can the science take us?},
  author={J. Graham and N. Jamieson and R. Rulach and S. Grimmond and D. Chang and A. Biankin},
  journal={Clinical Genetics},
  year={2015},
  volume={88}
}
The incidence of pancreatic ductal adenocarcinoma (PDAC) is steadily increasing and the annual death‐to‐incidence ratio approaches one. This is a figure that has not changed for several decades. Surgery remains the only chance of cure; however, only less than 20% of patients are amenable to operative resection. Despite successful surgical resection, the majority of the patients still succumb to recurrent metastatic disease. Therefore, there is an urgent need to develop novel therapeutic… Expand
15 Citations
Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor
...
1
2
...

References

SHOWING 1-10 OF 42 REFERENCES
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
  • J. Tabernero, T. Macarulla
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
Stromal expression of SPARC in pancreatic adenocarcinoma
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
...
1
2
3
4
5
...